# BPC-157 Medicine — A storybook of the pentadecapeptide research

> Thirty years of BPC-157 preclinical research, organized by tissue: gut, tendon, vasculature, spinal cord, and the modest but growing human record.

Fifteen amino acids. Thirty years of preclinical study. Three human pilot papers. This site reads them all — carefully, honestly, in order.

## The short version — what this compound is

BPC-157 is a synthetic fifteen-amino-acid peptide (a *pentadecapeptide*, meaning fifteen links in the chain) derived from a protein found in human stomach fluid. Scientists at the University of Zagreb began studying it in the 1990s, and over thirty years a large body of laboratory and animal research has built up around it.

The research is mostly in rodents. A single peptide has been studied across a striking range of injury types — gut wounds, torn tendons, spinal cord damage, vascular ischemia, and more — and the findings are consistently positive in those animal models. The honest caveat: only three small human pilot studies exist as of 2025, all uncontrolled and very early. BPC-157 is not approved for human use in any country, and the FDA placed it on a list restricting its use in compounded medications in 2023. WADA bans it in sport.

This site reads the published record carefully, chapter by chapter, and says plainly where the evidence is strong and where it is not. For a frank account of what people in research-use communities report — and what the safety concerns are — see [the effects page](/effects).

## What is BPC-157?

Body Protection Compound 157 is a synthetic pentadecapeptide — fifteen amino acids arranged in a specific sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. Its molecular weight is 1419.5 daltons. It does not occur freely in nature at these concentrations; it was identified, isolated, and then synthesized for research purposes by scientists at the University of Zagreb beginning in the 1990s.

What makes it unusual — the thing that has kept researchers returning to it across three decades and across a striking range of organ systems — is its stability. Unlike growth factors such as platelet-derived growth factor BB, BPC-157 survives intact in human gastric acid for more than twenty-four hours under research conditions [5]. Most peptides of its size do not. That stability is part of why a substance derived from the stomach lining can, in rodent models, be administered by mouth and still produce measurable effects in tissue far from the gut [4].

It has traveled under several names during its research history. Preclinical papers use *Pentadecapeptide BPC 157*. The pharmaceutical designation assigned for the inflammatory bowel disease trial that reached Phase II was PL 14736, also listed in earlier stages as PL-10 and PLD-116 [13]. The commercial research-chemical trade knows it simply as BPC-157. All of these names refer to the same fifteen-amino-acid sequence.

## Why so many organ systems?

This is the question that sits at the center of the BPC-157 research record, and it is worth asking plainly: how does a single fifteen-amino-acid peptide, administered in microgram-to-nanogram doses per kilogram of body weight, produce measurable effects in the gut, the tendon, the spinal cord, the vasculature, the kidney, the liver, the lung, and the brain — across different animal species, different routes of administration, and different injury models?

The current mechanistic answer, assembled across papers from the mid-1990s through 2025, centers on a few converging pathways. BPC-157 upregulates VEGFR2 — the vascular endothelial growth factor receptor 2 — on endothelial cells, triggering a downstream cascade through Akt and eNOS that drives angiogenesis and nitric oxide production [1]. It simultaneously engages a second pathway through Src kinase and Caveolin-1 to modulate vascular tone [2]. It activates FAK-paxillin signaling to drive fibroblast migration to wound sites, and it upregulates growth hormone receptor expression in tendon fibroblasts so that co-administration of growth hormone produces synergistic proliferation [3].

Perhaps most consequentially, it shifts macrophages from a pro-inflammatory M1 phenotype to a reparative M2 phenotype — reducing TNF-alpha, IL-6, and IFN-gamma — at almost any injury site it encounters [18]. A 2025 narrative review recorded that at wound sites, BPC-157 triggers the sequential upregulation of nineteen genes (including Akt1, Nos3, Vegfa, Src, and FAK) within ten minutes of application [18]. That speed suggests something closer to a biological-switch mechanism than a conventional pharmacological one: a short-lived compound activating a self-sustaining gene-expression cascade that outlasts its own presence in tissue.

None of this has been demonstrated at scale in humans. The research record is rodent-dominant, single-research-group-dominant, and — as of 2025 — supported by only three published human pilot studies [14, 15, 16]. That gap is the honest center of this site, and each chapter names it plainly.

## What the research shows — and what it does not

Across the animal literature, the findings are consistently positive and structurally diverse: gut fistula closure, tendon tensile strength recovery, accelerated corneal and skin wound healing, spinal cord motor function improvement, protection of kidney, lung, and liver tissue during ischemia-reperfusion injury, reversal of Parkinson's-like dopaminergic deficits in mice, and antidepressant-level effects in forced-swim tests [4, 5, 6, 7, 8, 9, 10, 11]. The breadth is the compound's most striking feature and, simultaneously, its most important epistemic difficulty: consistent positive findings across a wide array of rodent injury models could reflect genuine pleiotropic cytoprotection — or could reflect an artifact of the research methodology, the single-group publication pattern, or both.

A 2025 systematic review in *Sports Health* searched the database record through June 2024 and identified robust preclinical evidence for musculoskeletal repair alongside only three published human studies, all pilot-level [16]. The reviewers concluded that BPC-157 should not be recommended for clinical use until well-designed human trials exist. That is a straightforward finding, and this site does not argue with it.

What the three human pilots do show, held carefully at their appropriate weight: a 2021 intra-articular knee-pain study in sixteen patients found 87.5% reporting significant pain relief with no adverse events [20]; a 2024 intravesicular study in twelve treatment-refractory interstitial cystitis patients reported 80–100% symptom resolution at six weeks with no adverse events [14]; and a 2025 IV pharmacokinetic safety study in two healthy adults administered 10 mg and 20 mg infusions found no adverse events and no clinically meaningful laboratory changes [15]. All three are open-label, uncontrolled, and small. They are the beginning of a human evidence record, not its conclusion.

## A note on regulatory status

BPC-157 is not approved for human use in any jurisdiction. In September 2023, the United States Food and Drug Administration classified it as a Category 2 bulk drug substance, effectively prohibiting its inclusion in compounded medications for human therapeutic use. The World Anti-Doping Agency added it to its prohibited list under Section S0 (Non-Approved Substances) in 2022, banning it in and out of competition for athletes in WADA-governed sports.

The Phase II double-blind, placebo-controlled trial conducted by Pliva in Croatia (designation PL 14736) did complete with no reported toxicity, administered as a rectal enema for inflammatory bowel disease — but its full results were never submitted to a peer-reviewed journal, and the compound never advanced to regulatory submission in any market [13].

This site reads and summarizes the published research record. The chapters that follow are organized by tissue system, because that is how the literature is organized — and because thirty years of careful study of one small compound across many organ systems is, whatever its current regulatory standing, a genuinely interesting body of science.

## The chapters ahead

The research page organizes the evidence by chapter: the gastrointestinal story, where the compound originated and where it first proved its oral stability [4, 13]; the musculoskeletal story, where growth hormone receptor upregulation and FAK-paxillin signaling produce some of the most mechanistically specific findings in the record [3, 18]; the vascular story, where the VEGFR2-Akt-eNOS cascade has been validated at the molecular level in both cell culture and live animal models [1, 2]; the neuroprotection chapter, where spinal cord injury recovery and bidirectional neurotransmitter modulation extend the reach of the compound into territory that seems, at first, almost implausible [6, 8, 11]; the remote organ protection chapter, where a single 20 μg/kg intraperitoneal dose in rats significantly reduced histopathological damage in kidney, lung, and liver tissue simultaneously [9]; and, finally, the small sky-blue chapter — three human pilots, told exactly as they are, without embellishment.

The dosage page frames all dose data in the language of the studies that produced it: rodent models report doses in micrograms or nanograms per kilogram; the two human pilots that used a specified dose recorded 10 mg and 20 mg intravenously, and 10 mg intravesicularly. No dose recommendation for human use appears on this site, because the research record does not support one.

The glossary on the FAQ page defines the signaling terms — VEGFR2, eNOS, FAK-paxillin, M1-to-M2 macrophage polarization — so that any reader arriving from a general search can follow the mechanism chapters without prior biochemistry training. The references page lists every citation used on this site with its DOI or PubMed URL, so the underlying studies are always one click away.

---

An editorial record of peer-reviewed research — not a clinic, not a vendor, and not a prescription.